Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
NAQUIVAL is a fixed-dose combination tablet containing reserpine (an alkaloid antihypertensive) and trichlormethiazide (a thiazide diuretic) approved in 1960 for hypertension management. This oral combination works synergistically to reduce blood pressure through sympathetic inhibition and sodium/fluid depletion. The product represents a classic era of antihypertensive therapy now largely superseded by modern agents.
Product approaching loss of exclusivity with minimal linked job opportunities, indicating a small or declining brand team focused on managing transition and niche patient populations.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NAQUIVAL offers minimal career growth opportunity given the zero linked job count and approaching loss of exclusivity; roles are primarily focused on managing decline, optimizing pricing in niche segments, and supporting the transition to newer products. This assignment is best suited for professionals seeking experience in legacy product management, generic/branded transition strategy, or cost containment rather than career advancement or market expansion.
Worked on NAQUIVAL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.